Congress Wealth Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Congress Wealth Management’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-90,000	Closed	-$26.8K	–	627
2023 Q2	$26.8K	Hold	90,000	–	–	﹤0.01%	549
2023 Q1	$38.9K	Buy	+90,000	New	+$69.1K	﹤0.01%	550
2022 Q4	–	Sell	-20,000	Closed	-$46K	–	593
2022 Q3	$46K	Hold	20,000	–	–	﹤0.01%	541
2022 Q2	$44K	Buy	+20,000	New	+$139K	﹤0.01%	545

Congress Wealth Management's GRNA Position: Q3 2023 in Review

Congress Wealth Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 90,000 shares — an estimated $26.8K sold.

Congress Wealth Management first reported a position in GRNA in Q2 2022 and held it in 4 quarters. The position peaked at $46K in Q3 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Congress Wealth Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Congress Wealth Management sold 90,000 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $26.8K.
Congress Wealth Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q2 2022 and held it in 4 quarters.
Congress Wealth Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $46K in Q3 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Congress Wealth Management's 13F filing for Q3 2023, filed 30 Oct 2023.